Citius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products. Its LYMPHIR, an FDA-approved product, is a targeted immunotherapy for the treatment of cutaneous T-cell lymphoma. The company's late-stage pipeline includes Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections; Halo-Lido, a corticosteroid-lidocaine topical formulation to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; and NoveCite, a mesenchymal stem cell therapy for the treatment of ARDS. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey. Show more

11 Commerce Drive, Cranford, NJ, 07016, United States

https://citiuspharma.com

Biotechnology

Healthcare

Start AI Chat

Market Cap

20.14M

52 Wk Range

$0.63 - $2.48

Previous Close

$0.90

Open

$0.88

Volume

404,571

Day Range

$0.81 - $0.90

Enterprise Value

14.95M

Cash

7.721M

Avg Qtr Burn

-13.01M

Insider Ownership

2.20%

Institutional Own.

7.69%

Qtr Updated

12/31/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
LYMPHIR (Denileukin Diftitox-cxdl, E7777) Details T-cell lymphoma	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Mino-Lok Details Catheter related blood stream infections	Phase 3 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Halo-Lido (CITI-102) Details Hemorrhoids	Phase 2b Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Lymphir/Denileukin Diftitox-Cxdl (E7777) (IL-2R-Directed Cytotoxin) Details High-Risk Relapsed Or Refractory Diffuse Large B-Cell Lymphoma	Phase 1 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Pembrolizumab (KEYTRUDA®) + LYMPHIR™ Details Solid tumor/s	Phase 1 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.